Preoperative Treatment of Locally Advanced Rectal CancerDeborah Schrag, Harvey J. Mamon, Qian Shi et al.|New England Journal of Medicine|2023Cited by 440
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 studyArvind Dasari, Cathy Eng, Andrea Sartore‐Bianchi et al.|The Lancet|2023Cited by 319
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 StudyAkihito Kawazoe, Reinhard Depenbusch, Rui‐Hua Xu et al.|Journal of Clinical Oncology|2024Cited by 77
Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC).Frank A. Sinicrope, Jeffrey A. Meyerhardt, Fang‐Shu Ou et al.|Journal of Clinical Oncology|2025Cited by 47
Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the PancreasLeila T. Tchelebi, Joseph M. Herman, Diana Segovia et al.|International Journal of Radiation Oncology*Biology*Physics|2024Cited by 31